Atty. Dkt. No. 035394-0295

JC20 Rec'd PCT/PTO 1 3 MAY 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Irina A. BUHIMSCHI et al.

Title:

BIOMARKERS FOR INTRO-AMNIOTIC INFLAMMATION

Int'l. Appl. No.:

PCT/US2003/036120

Int'l. Filing

November 13, 2003

Date:

Examiner:

Unassigned

Art Unit:

Unassigned

<u>UNDER 37 CFR §1.56</u>

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

Atty. Dkt. No. 035394-0295

RELEVANCE OF EACH DOCUMENT

JC20 Rec'd PCT/PTO 1 3 MAY 2005

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. A copy of the cited references listed in the Search Report is not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

FOLEY & LARDNER LLP
Customer Number: 22428

Telephone:

(202) 672-5404

Facsimile:

(202) 672-5399

Stephen A. Bent

Attorney for Applicant Registration No. 29,768

JC20 Rec'd P PTO 1 3 NOTA PROPER (08-00)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

inger the Paper	work Reduction Act of T	995, no persons	are required to res	pond to a collection of information diffess it contain	15 a Valid OF 15 CONTROL HAMBEL.			
	Substitute fo	or form 1449B/P	TO .		Complete in Known Z 1, 6 0 h			
	INFORMAT	ION DISCLOSU	RE	Application Number	Anabetyried 224074			
	STATEMEN	T BY APPLICAL	NT	Filing Date	May 12, 2005			
	Data Culturia	and May 12 20	205	First Named Inventor	Irina A. Buhimschi			
	Date Submit	ted: May 13, 20	JU5	Group Art Unit	Unassigned			
(use as many sheets as necessary)				Examiner Name	Unassigned			
Sheet	2	of	2	Attorney Docket Number	035394-0295			

-	-	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1						
	A14	RJ PASSEY et al., "A null mutation in the inflammation-associated \$100 protein \$100A8 causes early resorption of the mouse embryo", The Journal of Immunology, 1999, vol. 163, pp. 2209-2216.					
	A15	J. HITOMI et al., "A novel calcium-binding protein in amniotic fluid CAAF1: its molecular cloning and tissue distribution", Journal of Cell Science, 1996, vol. 109, pp. 805-815.					
,	A16	MA HOFMANN et al., "RAGE mediates a novel proinflammatory axis: a central cell surface receptor for \$100/Calgranulin polypeptides", Cell, 1999, vol. 97, pp. 889-901.					
	A17	Z YANG et al., "Proinflammatory properties of the human \$100 protein \$100A12", Journal of Leukocycte Biology, June 2001, vol. 69, pp. 986-994.					
	A18	T. VOGL et al., "\$100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14", The Journal of Biological Chemistry, 1999, vol. 274, no. 36, pp. 25291-25296.					
	 						
			+				
		•					

Examiner Signature	Date Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.